H
Hiroyuki Mano
Researcher at University of Tokyo
Publications - 308
Citations - 24554
Hiroyuki Mano is an academic researcher from University of Tokyo. The author has contributed to research in topics: Gene & Cancer. The author has an hindex of 66, co-authored 275 publications receiving 22190 citations. Previous affiliations of Hiroyuki Mano include Astellas Pharma & Nagasaki University.
Papers
More filters
Patent
EML4-ALK fusion gene
TL;DR: In this article, the authors found that a fusion gene present in some cancer patients is an oncogene and proposed a method for detecting the fusion protein or polynucleotide.
Journal ArticleDOI
DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel.
Kazuya Takamochi,Fumiyuki Takahashi,Yoshiyuki Suehara,Eiichi Sato,Shinji Kohsaka,Takuo Hayashi,Shigehisa Kitano,Toshihide Uneno,Shinya Kojima,Kengo Takeuchi,Hiroyuki Mano,Kenji Suzuki +11 more
TL;DR: DNA mismatch repair deficiency status cannot be used as a biomarker for immune checkpoint inhibitor treatment for lung adenocarcinoma, regardless of smoking status and mutation status of driver oncogenes.
Journal ArticleDOI
Gene expression profiling of human atrial myocardium with atrial fibrillation by DNA microarray analysis
Ruri Ohki,Keiji Yamamoto,Shuichi Ueno,Hiroyuki Mano,Yoshio Misawa,Katsuo Fuse,Uichi Ikeda,Kazuyuki Shimada +7 more
TL;DR: Findings suggest that about one hundred genes may play critical roles in the initiation or perpetuation of AF and the pathophysiology of atrial remodeling.
Journal ArticleDOI
MicroRNA‐31 is a positive modulator of endothelial–mesenchymal transition and associated secretory phenotype induced by TGF‐β
Akihiro Katsura,Hiroshi I. Suzuki,Hiroshi I. Suzuki,Toshihide Ueno,Hajime Mihira,Tomoko Yamazaki,Takahiko Yasuda,Tetsuro Watabe,Tetsuro Watabe,Hiroyuki Mano,Yoshitsugu Yamada,Kohei Miyazono +11 more
TL;DR: Global transcriptome analysis showed that constitutively active microRNA‐31 (miR‐31) positively regulates EndMT‐associated unique secretory phenotype (EndMT‐SP characterized by induction of multiple inflammatory chemokines and cytokines including CCL17, Cx3CL1, CXCL16, IL‐6 and Angptl2.
Patent
Di(arylamino)aryl compound
Kondoh Yutaka,Iikubo Kazuhiko,Kuromitsu Sadao,Nobuaki Shindo,Soga Takatoshi,Furutani Takashi,Itsuro Shimada,Matsuya Takahiro,Kazuo Kurosawa,Akio Kamikawa,Hiroyuki Mano +10 more
TL;DR: In this article, the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins.